Management Team and Advisors

Ravi Kumar, Ph.D.

Founder

Dr. Ravi Kumar founded ARKAY Therapeutics with a mission to provide sustained glycemic control for Type 2 diabetes patients. He served as the CEO from 2014-19 and in 2021. Dr. Kumar is a subject matter expert in translational medicine, clinical development and contribution of immune and inflammatory dysfunctions to the pathophysiology of metabolic, cardiovascular, autoimmune and chronic inflammatory diseases. He has over 3 decades of pharmaceutical industry experience in small-to-medium-to-large pharmaceutical companies including Pfizer. Served as the Co-Project Leader of the safer Celebrex (a selective Cox-2 inhibitor) program and managed external clinical research for the development of Prevnar 20 vaccine. Dr. Kumar is the inventor of ARKAY's patent "Formulations and Methods for Treatment of Metabolic Syndrome."  He also cloned and characterized the Angiotensin-converting Enzyme (ACE), the key rate-limiting enzyme in the regulation of Renin-Angiotensin-Aldosterone System (RAAS) over three decades ago at The Cleveland Clinic Foundation. ACE inhibitors are widely used for the clinical management of high blood pressure and hypertension. ACE gene variant ACE2 also serves as the receptor and mediates entry of SARS-CoV-2 into cells, the Corona virus that causes COVID. Dr. Kumar obtained M.S. and Ph.D. in Molecular Cell Biology from New York University (NYU) and an Executive Mini-MBA in Biopharma Innovation from Rutgers University Business School.   

 Read More

Stanley S. Schwartz, MD, FACP, FACE

Chief Medical Advisor

Emeritus Associate Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Dr. Stanley Schwartz has retired from a private practice in Ardmore, PA. where he saw
patients for 12 years. He had previously spent 32 years at the University of
Pennsylvania, leaving as an Emeritus Clinical Associate Professor of Medicine. Dr.
Schwartz received his MD in 1973 from the University of Chicago ; completed his
residency at the University of Pennsylvania; and did a fellowship in endocrinology and
metabolism at the University of Chicago.

Read More

Douglas Greene, MD.

Former Executive Vice President, CSO, Ikaria Pharmaceuticals. Professor of Internal Medicine, Director of the Michigan Diabetes Research and Training Center, and Chief, Division of Endocrinology & Metabolism at the University of Michigan School of Medicine

Advisor

Douglas Greene, MD, is Founder and Chief Consultant, DAGPHAMED LLC. Dr. Greene served as Executive Vice President, Chief Scientific Officer and Head, Research and Development, Ikaria Pharmaceuticals from May 2010 until July 2015. From April 2009 to April 2010, Dr Greene served as Senior Vice President and Senior Scientific Advisor at Sanofi-Aventis, a global pharmaceutical company. From August 2006 to March 2009, Dr Greene served as Senior Vice President and Chief Medical Officer of the US business at Sanofi-Aventis. From June 2003 to July 2006, Dr Greene served as Head of Corporate Regulatory Development at Sanofi-Aventis.

 Read More

Martin Ogletree, Ph.D.

Chief Scientific Advisor

Former Distinguished Research Fellow & Director of Thrombosis Research, Metabolic &
Cardiovascular Drug Discovery, Bristol-Myers Squibb and Merck

Dr. Martin Ogletree led thrombosis research in Cardiovascular Drug Discovery at Merck Research Labs and at Bristol-Myers Squibb (BMS). At Merck he also led target identification and validation for the cardiovascular franchise. At BMS he led the team that advanced ELIQUIS (apixaban) in drug discovery, preclinical and early clinical development. 

Read More

Casey Case, Ph.D.

Former Senior Vice President, 4D Molecular Therapeutics

Board Member

Dr. Casey Case is a veteran pharmaceutical industry executive. He has contributed to the success of biopharmaceutical companies such as OSI Pharmaceuticals, Tularik and Sangamo Biosciences. 

Read More

Paul Jeffrey, M.B.A.

Former Vice President, New Product Development & Commercialization, Pfizer

Board Member

Mr. Paul Jeffrey is an experienced business executive and advisor with over 35 years of pharmaceutical research, product development, marketing and business development experience. As vice president of early commercial development at Pfizer, he was responsible for the commercial development of the entire portfolio of Rx pipeline products in Primary Care.

Read More

Marvin Cohen, Ph.D.

Advisor, Clinical Pharmacology

Marvin Cohen, Ph.D is President and Principal Consultant, MBC Pharma Solutions, LLC. Previously he was most recently Director of Clinical Pharmacology, Bristol-Myers Squibb. Dr. Cohen has a broad background in Pharmaceutical Research and Development for over 30 years in clinical pharmacology, clinical pharmacokinetics, nonclinical pharmacokinetics, and biotransformation in cardiovascular, metabolic diseases, oncology, immuno-oncology, hematology, immunology, neuroscience, infectious diseases, and dermatology therapeutic areas for both large molecule biotherapeutics and small molecules.

Read More

Late Clifford M. Davidson

Intellectual Property Attorney, Founding Partner, Davidson, Davidson & Kappel, LLC

Advisor

Cliff Davidson is a founding partner at Davidson, Davidson & Kappel, LLC, an Intellectual Property law firm with offices in New York. He counsels pharmaceutical clients in pharmaceutical patent-related matters, including patent prosecution, freedom to operate and infringement opinions, due diligence and tech transfer, and litigation. He has assisted pharmaceutical and biotech companies in creating significant and valuable patent portfolios covering their proprietary technologies.

Read More